Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GSTO1 | P78417 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11350463 | 0.85 | L3MBTL1 (0.62) | L3MBTL1KDM4EHSD17B10MAPTKMT2A | |
| SCHEMBL20987763 | 0.84 | GSTO1 (0.48) | PI4KBGSTO1KDM4EHSD17B10MAPT | |
| SCHEMBL16123250 | 0.84 | TYR (0.49) | PI4KBGSTO1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL11508621 | 0.79 | GSTO1 (0.48) | PI4KBGSTO1 | |
| SCHEMBL11475672 | 0.77 | TGM2 (0.44) | GSTO1LMNA | |
| SCHEMBL12947791 | 0.76 | KDM4E (0.67) | PI4KBL3MBTL1KDM4EHSD17B10MAPT | |
| SCHEMBL16095753 | 0.76 | GSTO1 (0.47) | PI4KBGSTO1HSD17B10 | |
| SCHEMBL11635206 | 0.75 | GSTO1 (0.48) | PI4KBGSTO1 | |
| SCHEMBL664795 | 0.73 | L3MBTL1 (0.61) | PI4KBL3MBTL1KDM4EHSD17B10MAPT | |
| SCHEMBL8015293 | 0.72 | SMN1; SMN2 (0.65) | PI4KBL3MBTL1KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | PI4KB 467/4885L3MBTL1 4189/4885GSTO1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.